Ivelin Georgiev Archives
Jul. 20, 2022—In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.
Mar. 24, 2022—Vanderbilt's Ivelin Georgiev, PhD, has received a three-year, $750,000 award from The G. Harold and Leila Y. Mathers Foundation of Rye Brook, New York, to support research aimed at rapidly identifying potent, disease-fighting antibodies.
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
Oct. 29, 2020—An innovative Vanderbilt program that brings together scientists and artists with the shared goal of scientific communication is set to expand with support from a three-year grant from the Burroughs Wellcome Fund.
Jun. 23, 2020—Two Vanderbilt University Medical Center researchers -- Jennifer (Piper) Below, PhD, associate professor of Medicine, and Ivelin Georgiev, PhD, associate professor of Pathology, Microbiology and Immunology -- have been selected for the 2020 cohort of Chancellor Faculty Fellows at Vanderbilt University.
Dec. 12, 2019— by Allison Whitten The antibody discovery and vaccine development research fields may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues. Currently, due to technological constraints, it can take up to a year to...